BioInvent and CASI on their collaboration

In a BioStock Studio exclusive, Martin Welschof, CEO of BioInvent and Wei-Wu He, Chairman and CEO of the American biopharma company CASI Pharmaceuticals, joined...
BiBBInstruments FDA 2022

BiBBInstruments aims for US market entry in 2023

Lund-based BiBBInstruments is developing the world's first electric biopsy instrument, EndoDrill, with the ambition of facilitating and accelerating the diagnosis of some of the...
New management in Cyxone

New management in Cyxone

The board of Malmö-based company Cyxone recently announced a change in management. Carl-Magnus Högerkorp, Chief Operating Officer, steps in as acting CEO and replaces...

BioInvent in new potentially lucrative license agreement

BioInvent has entered into an option and license agreement with American Exelixis with a focus on the identification and development of new antibodies for...

CombiGene comments on positive news for Bluebird

An external expert committee has unanimously recommended FDA approval of two of Bluebird's gene therapy treatments. Thus, the prospect for Bluebird to launch the...
PolarCool international market expansion-2

PolarCool’s strategy for international expansion

As new deals made by Swedish medical device company PolarCool continue to pile on, it is quite clear that the company’s marketing strategy is...

Aptahem’s new CMO on her role and vision

Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting another piece of the puzzle in place for...
Promore Pharma fas II-studie

Last clinic visit completed in Promore Pharma’s ensereptide study

The most important activity for Promore Pharma in 2022 has been the phase IIa study with drug candidate ensereptide. The company announced earlier this...
Fortsatt tillväxt förutspås i Medicon Valley

Continued growth predicted in Medicon Valley

Medicon Valley, the cluster for life science around Öresund, is growing rapidly. A new survey shows that the Danish side of the cluster currently...
Migraine

Chordate’s CSO is looking forward to migraine study results

The medtech company Chordate Medical currently has two patient studies that are in the final stages and two studies in the planning stage. BioStock...